Results

1–10 of 192 results for Age-Related Macular Degeneration

Retro-Mode (RM): A Newer Insight Into Dry Age-Related Macular Degeneration
SHILPI H NARNAWARE, ICO ( Retina) , FAICO ( Vitreo-Retina)
Annual Meeting Talks
2025
Delayed Near-Infrared Analysis (DNIRA) Identifies Novel and Changing Features of Nonexudative (Dry) Age-Related Macular Degeneration (AMD): A Longitudinal Study
Shelley Boyd, MD, FRCS(C)
Annual Meeting Talks
2025
Changes in Hyperautofluorescence Area and RPE/Outer Retinal Layer Thickness in the Phase 2a SIGLEC Study Assessing AVD-104 for the Treatment of GA
Carl D. Regillo, MD
Annual Meeting Talks
2025
Accuracy of Initial Anti-VEGF Treatment Selection in Newly Diagnosed Neovascular Age-Related Macular Degeneration: Retina Specialist Choice vs Step Therapy
Prithvi Reddy Bomdica, MD, MBA
Annual Meeting Talks
2025
Longitudinal Validation of the Performance of an AI-Based Algorithm in a Home OCT Pivotal Study of Age-Related Macular Degeneration
S. Krishna Mukkamala, MD, FASRS
Annual Meeting Talks
2025
Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): Results From OPTIC and LUNA Trials
Mark R. Barakat, MD
Annual Meeting Talks
2025
PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Neovascular Age-Related Macular Degeneration: 52-Week Results
John A. Wells, MD, FACS
Annual Meeting Talks
2025
COAST: A Phase 3 Study of Intravitreal Sozinibercept Combined With Aflibercept in Participants With Neovascular Age-Related Macular Degeneration
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2025
Vision Outcomes From the DAVIO 2 Trial: A Phase 2 Trial of EYP-1901 vs Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration
Jennifer I. Lim, MD, FARVO, FASRS
Annual Meeting Talks
2025
Treatment Burden in Wet Age-Related Macular Degeneration Treated With EYP-1901 vs Aflibercept in DAVIO 2, a Phase 2 Clinical Trial
Avni P Finn, MD, MBA, FASRS
Annual Meeting Talks
2025